(Total Views: 409)
Posted On: 08/03/2021 3:34:12 PM
Post# of 153822
It should be obvious to anyone who actually knows anything about the company that both of today's articles on Endpoints/Fiercebiotech use inflammatory and charged language to try to scare any potential investors away from the stock.
This is how short syndicates work. They try to get individual investors to be afraid to buy the stock with articles like this, so that they won't even bother investigating the company.
Tell me that this isn't biased in its phraseology:
The analysis didn't "claim" to show it. It DID show it.
As someone else said, this is the response by 13-D (or possibly a short-seller who is well-connected in the biotech publishing industry)
This is how short syndicates work. They try to get individual investors to be afraid to buy the stock with articles like this, so that they won't even bother investigating the company.
Tell me that this isn't biased in its phraseology:
Quote:
Later, CytoDyn performed an “age adjustment” analysis claiming to show that leronlimab reduced mortality in older patients
The analysis didn't "claim" to show it. It DID show it.
As someone else said, this is the response by 13-D (or possibly a short-seller who is well-connected in the biotech publishing industry)
(6)
(0)
